MDX-210 bispecific antibody targeting HER-2 receptor on cancers data

MEDX announced Phase II findings from an ongoing study, showing

Read the full 104 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE